Acorda Therapeutics, Inc. Nasdaq

Equities

ACOR

US00484M7002

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 15:41:31 2024-07-17 EDT			5-day change	1st Jan Change
0.15 ^USD	-25.00%		-11.76%	-99.01%

07-10	Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.	CI
07-03	Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.	CI

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Year 2020

January 15, 2020 at 07:00 am

Acorda Therapeutics, Inc. provided revenue guidance for the year 2020. Total product net revenue for the full year 2020 is expected to be $120 - $150 million, with total revenue expected to be $130 - $160 million.

Latest news about Acorda Therapeutics, Inc.

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.	07-09	CI
Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.	07-03	CI
First Amended Joint Liquidation Plan and Disclosure Statement Filed by Acorda Therapeutics, Inc.	07-01	CI
Motion for Asset Sale Approved for Acorda Therapeutics, Inc.	06-12	CI
Acorda Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Liquidation Plan and Disclosure Statement Filed by Acorda Therapeutics, Inc.	05-10	CI
Final DIP Financing Approved for Acorda Therapeutics, Inc.	05-03	CI
Bidding Procedure Approved for Acorda Therapeutics, Inc.	04-29	CI
Acorda Therapeutics Delisted from Nasdaq, Now Trading on OTC Pink Market	04-15	MT
Interim DIP Financing Approved for Acorda Therapeutics, Inc.	04-05	CI
Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from S&P TMI Index	04-04	CI
Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.	03-31	CI
Transcript : Acorda Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023	23-08-08

Chart Acorda Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinsonâs disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	118B
ARGENX SE	+23.26%	27.87B
BIONTECH SE	-18.07%	20.95B
GENMAB A/S	-15.13%	16.92B
BEIGENE, LTD.	-14.81%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.84B
WUXI APPTEC CO., LTD.	-46.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+52.34%	14.08B

Bio Therapeutic Drugs